MCID: OVR049
MIFTS: 58

Ovarian Disease

Categories: Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Disease

MalaCards integrated aliases for Ovarian Disease:

Name: Ovarian Disease 12 15
Ovarian Dysfunction 12 55 15
Ovarian Diseases 55 44 73
Disorder of Endocrine Ovary 73
Ovarian Disorders 43

Classifications:



External Ids:

Disease Ontology 12 DOID:1100 DOID:1414
MeSH 44 D010049
NCIt 50 C26841
SNOMED-CT 68 5552004
ICD9CM 35 256.3 256.39
ICD10 33 E28 E28.3 E28.9

Summaries for Ovarian Disease

MedlinePlus : 43 The ovaries are part of the female reproductive system. Women have two ovaries, one on each side of the uterus. Each ovary is about the size and shape of an almond. The ovaries produce and store a woman's eggs. During ovulation, an ovary releases an egg. If that egg is fertilized by a sperm, a pregnancy can occur. Ovaries also make the female hormones estrogen and progesterone. When a woman goes through menopause, her ovaries stop making those hormones and releasing eggs. Problems with the ovaries include Ovarian cancer Ovarian cysts and polycystic ovary syndrome Primary ovarian insufficiency Ovarian torsion, a twisting of the ovary

MalaCards based summary : Ovarian Disease, also known as ovarian dysfunction, is related to estrogen excess and ovarian hyperstimulation syndrome, and has symptoms including pelvic pain and mittelschmerz. An important gene associated with Ovarian Disease is GNRH1 (Gonadotropin Releasing Hormone 1), and among its related pathways/superpathways are TGF-Beta Pathway and Prolactin Signaling Pathway. The drugs Metformin and Letrozole have been mentioned in the context of this disorder. Affiliated tissues include ovary, uterus and pituitary, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Disease Ontology : 12 An ovarian disease that is characterized by irregular or absent ovulation.

Wikipedia : 76 Ovarian diseases are conditions that happen to young women and can affect their reproductive system and... more...

Related Diseases for Ovarian Disease

Diseases in the Ovarian Disease family:

Ovarian Insufficiency, Familial Fmr1-Related Primary Ovarian Insufficiency
Ovarian Insufficiency Due to Fsh Resistance

Diseases related to Ovarian Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 151)
# Related Disease Score Top Affiliating Genes
1 estrogen excess 32.6 CYP19A1 FSHR PRL SHBG
2 ovarian hyperstimulation syndrome 32.1 AMH CGA CYP19A1 FSHR GNRH1
3 anovulation 31.9 SHBG PRL INS IGF1 GNRH1 FSHR
4 premature menopause 31.8 AMH BRCA1 BRCA2 GNRH1
5 polycystic ovary syndrome 31.8 SHBG PRL INS IGFBP1 IGF1 GNRH1
6 ovarian cyst 31.7 FOXL2 MUC16 PRL
7 premature ovarian failure 1 31.0 ZP3 SHBG PRL GNRH1 GDF9 GALT
8 hyperprolactinemia 30.3 GNRH1 IGF1 PRL SHBG
9 insulin-like growth factor i 30.2 IGF1 IGFBP1 INS PRL SHBG
10 amenorrhea 30.2 BMP15 FSHR GNRH1 PRL SHBG
11 hyperinsulinism 30.2 IGF1 IGFBP1 INS SHBG
12 mccune-albright syndrome 30.1 AMH CYP19A1 IGF1 PRL
13 hyperandrogenism 30.0 SHBG PRL INS IGFBP1 IGF1 GNRH1
14 acromegaly 29.9 IGF1 IGFBP1 INS PRL
15 prader-willi syndrome 29.9 GNRH1 IGF1 IGFBP1 INS
16 infertility 29.9 CYP19A1 FSHR GDF9 GNRH1 PRL ZP3
17 acanthosis nigricans 29.8 IGF1 INS PRL SHBG
18 pituitary gland disease 29.8 GNRH1 IGF1 INS PRL
19 luteoma 29.7 CGA CYP19A1
20 ovarian cancer 29.5 BRCA1 BRCA2 FSHR GNRH1 MUC16 TNF
21 anorexia nervosa 29.4 IGF1 IGFBP1 PRL
22 endometrial cancer 29.4 MUC16 INS IGFBP1 IGF1 GNRH1 CYP19A1
23 breast cancer 29.2 BRCA1 BRCA2 CYP19A1 GNRH1 IGF1 INS
24 mullerian aplasia and hyperandrogenism 11.2
25 galactosemia 11.0
26 leukoencephalopathy with vanishing white matter 11.0
27 ovarian stromal hyperthecosis 10.8
28 ovarian dysgenesis 2 10.8
29 premature ovarian failure 2a 10.8
30 premature ovarian failure 2b 10.8
31 premature ovarian failure 3 10.8
32 premature ovarian failure 5 10.8
33 premature ovarian failure 6 10.8
34 premature ovarian failure 10 10.8
35 premature ovarian failure 7 10.8
36 premature ovarian failure 8 10.8
37 premature ovarian failure 9 10.8
38 premature ovarian failure 11 10.8
39 premature ovarian failure 12 10.8
40 premature ovarian failure 13 10.8
41 premature ovarian failure 14 10.8
42 male reproductive system disease 10.4 GNRH1 IGF1 SHBG
43 pancreas disease 10.4 IGF1 INS TNF
44 pituitary infarct 10.4 GNRH1 IGF1 PRL
45 hyperproinsulinemia 10.4 IGFBP1 INS SHBG
46 pituitary apoplexy 10.4 GNRH1 INS PRL
47 sheehan syndrome 10.4 IGF1 INS PRL
48 hypergonadotropic hypogonadism and partial alopecia 10.4
49 hyperpituitarism 10.4 IGF1 INS PRL
50 empty sella syndrome 10.4 GNRH1 IGF1 PRL

Graphical network of the top 20 diseases related to Ovarian Disease:



Diseases related to Ovarian Disease

Symptoms & Phenotypes for Ovarian Disease

UMLS symptoms related to Ovarian Disease:


pelvic pain, mittelschmerz

MGI Mouse Phenotypes related to Ovarian Disease:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.39 AMH BMP15 BRCA1 BRCA2 CGA CYP19A1
2 homeostasis/metabolism MP:0005376 10.25 AMH BRCA1 BRCA2 CGA CYP19A1 FOXL2
3 cellular MP:0005384 10.22 BRCA1 BRCA2 CYP19A1 FMR1 FSHR GALT
4 growth/size/body region MP:0005378 10.21 BRCA1 BRCA2 CGA CYP19A1 FMR1 FOXL2
5 immune system MP:0005387 10.11 BRCA1 BRCA2 CYP19A1 FSHR GALT GNRH1
6 integument MP:0010771 10.02 BRCA1 BRCA2 CYP19A1 FMR1 FSHR GNRH1
7 adipose tissue MP:0005375 9.97 BRCA1 CYP19A1 FSHR IGF1 INS TNF
8 liver/biliary system MP:0005370 9.8 CYP19A1 GALT GNRH1 IGFBP1 INS PRL
9 neoplasm MP:0002006 9.76 AMH BRCA1 BRCA2 FSHR GNRH1 IGF1
10 nervous system MP:0003631 9.73 BRCA1 BRCA2 CGA CYP19A1 FMR1 FSHR
11 reproductive system MP:0005389 9.55 AMH BMP15 BRCA1 BRCA2 CGA CYP19A1

Drugs & Therapeutics for Ovarian Disease

Drugs for Ovarian Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 717)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
2
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 112809-51-5 3902
3
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 135968-09-1
4
Drospirenone Approved Phase 4,Phase 3,Phase 1,Not Applicable 67392-87-4 68873
5 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
6
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 427-51-0
7
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
8
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
9
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-63-6 5991
10
Simvastatin Approved Phase 4,Phase 3,Not Applicable 79902-63-9 54454
11
Resveratrol Approved, Experimental, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 501-36-0 445154
12
Orlistat Approved, Investigational Phase 4,Phase 2,Not Applicable 96829-58-2 3034010
13
Ganirelix Approved Phase 4,Phase 2,Not Applicable,Early Phase 1 123246-29-7, 124904-93-4 25081094
14
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
15
Menotropins Approved Phase 4,Phase 2,Phase 1,Not Applicable 61489-71-2, 9002-68-0 5360545
16
Pioglitazone Approved, Investigational Phase 4,Not Applicable,Early Phase 1 111025-46-8 4829
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
19
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
20
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
21
Acarbose Approved, Investigational Phase 4,Not Applicable 56180-94-0 441184
22
Zinc Approved, Investigational Phase 4,Early Phase 1,Not Applicable 7440-66-6
23
Hydrocortisone acetate Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-03-3
24
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 50-23-7 5754
25
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 216974-75-3
26
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
27
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
28
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
29
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 71-58-9
30
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 763113-22-0 23725625
31
Buserelin Approved, Investigational Phase 4 57982-77-1
32
Leuprolide Approved, Investigational Phase 4,Phase 2,Not Applicable,Early Phase 1 53714-56-0 657181 3911
33
Nafarelin Approved Phase 4 76932-56-4 25077649 16129618
34
Aspirin Approved, Vet_approved Phase 4,Phase 2,Early Phase 1 50-78-2 2244
35
Liraglutide Approved Phase 4,Phase 3 204656-20-2 44147092
36
Alogliptin Approved Phase 4 850649-61-5 11450633
37
Danazol Approved Phase 4 17230-88-5 28417
38
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 616-91-1 12035
39
Citalopram Approved Phase 4 59729-33-8 2771
40
Racepinephrine Approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 329-65-7 838
41
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 51-43-4 5816
42
Tranexamic Acid Approved Phase 4 1197-18-8 5526
43
Norethindrone Approved Phase 4,Phase 2,Not Applicable,Early Phase 1 68-22-4 6230
44
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
45
Hydroxocobalamin Approved Phase 4,Not Applicable 13422-51-0 11953898 44475014
46
Methylcobalamin Approved, Experimental, Investigational Phase 4,Not Applicable 13422-55-4
47
Nicotinamide Approved, Investigational Phase 4,Phase 2,Phase 1 98-92-0 936
48
Rosiglitazone Approved, Investigational Phase 4,Not Applicable 122320-73-4 77999
49
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
50
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741

Interventional clinical trials:

(show top 50) (show all 2423)
# Name Status NCT ID Phase Drugs
1 Metformin for the Treatment of Unexplained Oligozspermia Unknown status NCT01529177 Phase 4 Metformin / clomid / hCG;Clomiphene citrate / hCG
2 Administration of Single High Dose Letrozole for Ovulation Induction Unknown status NCT02703649 Phase 4 Letrozole
3 Filgrastim for Premature Ovarian Insufficiency Unknown status NCT02783937 Phase 4 Saline
4 The Impact on Ovarian Reserve After Single-port, Two-port, or Four-port Access Laparoscopic Ovarian Cyst Enucleation Unknown status NCT01631253 Phase 4
5 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
6 Effects of ADSC Therapy in Women With POF Unknown status NCT01853501 Phase 4
7 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
8 Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT02766803 Phase 4 Simvastatin and micronized trans-resveratrol
9 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
10 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
11 Metformin in Infertile PCOS Patients Unknown status NCT00501904 Phase 4 Metformin
12 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
13 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
14 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
15 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
16 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
17 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
18 Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS Completed NCT01815138 Phase 4 hCG;hCG
19 Endometrial Receptivity After GnRH Agonist Triggering Completed NCT01500863 Phase 4 hCG;triptorelin;Triptorelin, estradiol valerate, micronized vaginal progesterone;triptorelin, hCG;triptorelin, hCG;triptorelin, recombinant LH
20 Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles Completed NCT00627406 Phase 4 Buserelin and Pregnyl;Pregnyl;Buserelin and Pregnyl;Pregnyl
21 The Use of GnRH Agonist Trigger in the Prevention of OHSS Completed NCT00349258 Phase 4 Leuprolide acetate
22 Follicular Steroid Genesis in Controlled Ovarian Stimulation Completed NCT02738580 Phase 4 COS with GnRH antagonists and rFSH;COS with GnRH antagonists and HP-HMG
23 FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST) Completed NCT01969201 Phase 4 Urofollitrophin;Follitrophin alpha
24 Gonadotrophin Dosage Using a Threshold Nomogram for Ovulation Induction in WHO Group II Anovulatory Infertility Completed NCT01250821 Phase 4 Menopur
25 Short Versus Long Protocol for IVF and IVF+ICSI Completed NCT00756028 Phase 4 Patients receiving short protocol IVF/ICSI-treatment.;Long protocol
26 Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders Completed NCT00417066 Phase 4 Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands);Arvekap 0.1mg (Triptorelin, Ipsen, France)
27 Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS Completed NCT02670304 Phase 4 letrozole;Aspirin
28 Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS Completed NCT03644212 Phase 4 Vitamin D3
29 The Role of Estrogen in Luteinizing Hormone Surge and Ovulation Completed NCT01999569 Phase 4 Letrozole
30 Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome Completed NCT03122041 Phase 4 Sitagliptin
31 Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss Completed NCT02941445 Phase 4 sitagliptin and metformin;Metformin
32 The Effect of Metformin on Different Hormones in PCOS Patients Completed NCT02568488 Phase 4 Metformin
33 Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome Completed NCT02483299 Phase 4 Metformin;Glucophage tablets and Victoza
34 Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOS Completed NCT02352597 Phase 4 phytoestrogen;estradiol valerate;clomiphene citrate
35 PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome Completed NCT02187250 Phase 4 metformin;liraglutide;roflumilast
36 PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome Completed NCT02037672 Phase 4 metformin;metformin and roflumilast
37 Adding L-Carnitine to Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome Completed NCT03630341 Phase 4 Clomiphene Citrate 50mg;L-carnitine;Placebo Oral Tablet
38 Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
39 Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin Completed NCT01911468 Phase 4 metformin;liraglutide;metformin and liraglutide
40 Polycystic Ovary Syndrome and Liraglutide Completed NCT01899430 Phase 4 liraglutide;metformin
41 The Effect of a Liraglutide on IVF in Obese PCOS Completed NCT03353948 Phase 4 MET;COMBI
42 Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism Completed NCT01721915 Phase 4 Vitamin D supplementation;Placebo
43 Medical Nutrition Therapy Plus Transgestational Metformin For Preventing Gestational Diabetes In High Risk Mexican Women Completed NCT01675310 Phase 4 medical nutrition therapy + metformin
44 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
45 A Random Clinical Trial (RCT) of the Impact of Electrocoagulation on Ovarian Reserve Completed NCT00746278 Phase 4
46 The Impact of Electrocoagulation on Ovarian Reserve After Laparoscopic Excision of Ovarian Cyst Completed NCT00713778 Phase 4
47 The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS Completed NCT02866786 Phase 4 Metformin;ethinyl estradiol and cyproterone acetate
48 Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. Completed NCT03015909 Phase 4 Somatropin
49 hMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVF Completed NCT01365936 Phase 4 HMG;rFSH
50 Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity Completed NCT02909933 Phase 4 liraglutide;metformin and liraglutide

Search NIH Clinical Center for Ovarian Disease

Cochrane evidence based reviews: ovarian diseases

Genetic Tests for Ovarian Disease

Anatomical Context for Ovarian Disease

MalaCards organs/tissues related to Ovarian Disease:

41
Ovary, Uterus, Pituitary, Bone, Testes, Heart, Prostate

Publications for Ovarian Disease

Articles related to Ovarian Disease:

(show top 50) (show all 577)
# Title Authors Year
1
Crosstalk between advanced glycation end products and vitamin D: A compelling paradigm for the treatment of ovarian dysfunction in PCOS. ( 30170183 )
2019
2
Combined Cabergoline and Metformin in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: Methodological Concerns. ( 29896007 )
2018
3
Reproductive performance in dairy cows with cystic ovarian disease after single treatment with buserelin acetate or dinoprost. ( 29848852 )
2018
4
Tumor necrosis factor alpha versus LH and androstendione as a reliable predictor of spontaneous ovulation after laparoscopic ovarian drilling for women with clomiphene citrate resistance polycystic ovarian disease. ( 29408743 )
2018
5
A Cross-sectional Study on the Proportion of Anxiety and Depression and Determinants of Quality of Life in Polycystic Ovarian Disease. ( 29875533 )
2018
6
Alterations in key metabolic sensors involved in bovine cystic ovarian disease. ( 30121546 )
2018
7
Expression of TGFBR1, TGFBR2, TGFBR3, ACVR1B and ACVR2B is altered in ovaries of cows with cystic ovarian disease. ( 30120850 )
2018
8
Histone deacetylase: A potential therapeutic target for ovarian dysfunction. ( 28930559 )
2018
9
Identification of the first homozygous POLG mutation causing non-syndromic ovarian dysfunction. ( 29992832 )
2018
10
Early Detection of Ovarian Dysfunction by Anti-Mullerian Hormone in Adolescent and Young Adult-Aged Survivors of Childhood Cancer. ( 30281375 )
2018
11
Polycystic Ovarian Disease (Stein-Leventhal Syndrome) ( 29083730 )
2017
12
Efficacy of Combined Cabergoline and Metformin Compared to Metformin Alone on Cycle Regularity in Patients with Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial. ( 28867888 )
2017
13
Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. ( 28479118 )
2017
14
Thyroid function/antibodies in sudanese women with polycystic ovarian disease. ( 28344960 )
2017
15
The role of regulatory T cells in thymectomy-induced autoimmune ovarian disease. ( 28660639 )
2017
16
Natural history of autoimmune primary ovarian insufficiency in patients with Addison's disease: from normal ovarian function to overt ovarian dysfunction. ( 28733292 )
2017
17
Ovarian dysfunction associated with zona pellucida-based immunocontraceptive vaccines. ( 27771114 )
2017
18
Biological and biomechanical analysis of two types of mesenchymal stem cells for intervention in chemotherapy-induced ovarian dysfunction. ( 27928675 )
2017
19
Selective deletion of Pten in theca-interstitial cells leads to androgen excess and ovarian dysfunction in mice. ( 28137614 )
2017
20
Parabens Accelerate Ovarian Dysfunction in a 4-Vinylcyclohexene Diepoxide-Induced Ovarian Failure Model. ( 28208728 )
2017
21
Strategies for overcoming oncological treatment-related ovarian dysfunction - literature review. ( 28604126 )
2017
22
Polycystic ovarian disease and associated factors. ( 27075885 )
2016
23
A novel method of extraction of bamboo seed oil (Bambusa bambos Druce) and its promising effect on metabolic symptoms of experimentally induced polycystic ovarian disease. ( 27127318 )
2016
24
BMP2, 4 and 6 and BMPR1B are altered from early stages of bovine cystic ovarian disease development. ( 27486268 )
2016
25
Bidirectional Estrogen-Like Effects of Genistein on Murine Experimental Autoimmune Ovarian Disease. ( 27834809 )
2016
26
Involvement of Matrix Metalloproteinases and their Inhibitors in Bovine Cystic Ovarian Disease. ( 27993358 )
2016
27
Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials. ( 26657509 )
2016
28
Role of Glucocorticoids in Cystic Ovarian Disease: Expression of Glucocorticoid Receptor in the Bovine Ovary. ( 26677854 )
2016
29
Genetic Rodent Models of Obesity-Associated Ovarian Dysfunction and Subfertility: Insights into Polycystic Ovary Syndrome. ( 27375552 )
2016
30
Complex X-Chromosomal Rearrangements in Two Women with Ovarian Dysfunction: Implications of Chromothripsis/Chromoanasynthesis-Dependent and -Independent Origins of Complex Genomic Alterations. ( 28099951 )
2016
31
Oral contraceptive pills induced hemichorea in an adolescent female with polycystic ovarian disease. ( 25878392 )
2015
32
Involvement of PAPP-A and IGFR1 in Cystic Ovarian Disease in Cattle. ( 26031184 )
2015
33
Molecular aspects of bovine cystic ovarian disease pathogenesis. ( 25767139 )
2015
34
Altered Expression of Pro-inflammatory Cytokines in Ovarian Follicles of Cows with Cystic Ovarian Disease. ( 26065705 )
2015
35
"Empiric" inositol supplementation in normal-weight non insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects. ( 25687659 )
2015
36
Anti-mA1llerian hormone and insulin-like 3 levels in healthy normal-weight ovulatory and anovulatory eumenorrheic late adolescent females: potential early biomarkers of ovarian dysfunction? ( 26579638 )
2015
37
Authors' reply to: "Empiric" inositol supplementation in normal-weight non-insulin resistant women with polycystic ovarian disease: from the absence of benefit to the potential adverse effects. ( 25687660 )
2015
38
A novel serum microRNA panel to discriminate benign from malignant ovarian disease. ( 25451316 )
2015
39
Impaired insulin signaling pathway in ovarian follicles of cows with cystic ovarian disease. ( 25813700 )
2015
40
Disrupted hyaluronan binding protein 1 (HABP1) expression: one of the key mediator for ovarian dysfunction in polycystic ovary rat. ( 25300617 )
2015
41
Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction. ( 26132932 )
2015
42
Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features. ( 26269538 )
2015
43
Impact of Chemotherapy-Induced Ovarian Dysfunction on Response to Neoadjuvant Chemotherapy in Breast Cancer. ( 26275780 )
2015
44
Women with clomiphene citrate resistant polycystic ovarian disease: predictors of spontaneous ovulation after laparoscopic ovarian drilling. ( 24576485 )
2014
45
Ovarian dysfunction, obesity and pituitary tumors in female mice following neonatal exposure to low-dose diethylstilbestrol. ( 25450423 )
2014
46
Role of activin, inhibin, and follistatin in the pathogenesis of bovine cystic ovarian disease. ( 25001504 )
2014
47
Polycystic ovarian disease: still an enigma! ( 24685855 )
2014
48
Can treatment for polycystic ovarian disease induce ovarian tumour? A case report. ( 24596770 )
2014
49
Epidemiological description of cystic ovarian disease in argentine dairy herds: risk factors and effects on the reproductive performance of lactating cows. ( 25292292 )
2014
50
Altered expression of transforming growth factor-beta isoforms in bovine cystic ovarian disease. ( 25112788 )
2014

Variations for Ovarian Disease

Expression for Ovarian Disease

Search GEO for disease gene expression data for Ovarian Disease.

Pathways for Ovarian Disease

GO Terms for Ovarian Disease

Cellular components related to Ovarian Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 AMH BMP15 CGA GDF9 GNRH1 IGF1
2 Golgi lumen GO:0005796 9.43 CGA INS MUC16
3 extracellular space GO:0005615 9.4 AMH BMP15 CGA GDF9 GNRH1 IGF1
4 endosome lumen GO:0031904 9.32 INS PRL
5 lateral element GO:0000800 9.16 BRCA1 BRCA2

Biological processes related to Ovarian Disease according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.98 CGA GDF9 IGF1 INS PRL
2 positive regulation of gene expression GO:0010628 9.93 AMH BRCA1 IGF1 INS TNF
3 positive regulation of transcription, DNA-templated GO:0045893 9.87 BMP15 BRCA1 BRCA2 FOXL2 IGF1 TNF
4 cellular protein metabolic process GO:0044267 9.83 BMP15 IGF1 IGFBP1 INS PRL
5 BMP signaling pathway GO:0030509 9.73 AMH BMP15 GDF9
6 regulation of MAPK cascade GO:0043408 9.7 BMP15 FSHR GDF9
7 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.69 BRCA1 BRCA2 TNF
8 mammary gland development GO:0030879 9.65 BRCA2 CYP19A1 PRL
9 negative regulation of lipid catabolic process GO:0050995 9.61 INS TNF
10 positive regulation of calcineurin-NFAT signaling cascade GO:0070886 9.61 IGF1 TNF
11 positive regulation of glycogen biosynthetic process GO:0045725 9.6 IGF1 INS
12 regulation of osteoclast differentiation GO:0045670 9.59 FSHR TNF
13 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.58 BRCA1 BRCA2
14 female gamete generation GO:0007292 9.58 BMP15 FSHR GDF9
15 regulation of protein secretion GO:0050708 9.57 INS TNF
16 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.56 FSHR IGF1 INS TNF
17 ovulation cycle GO:0042698 9.55 GNRH1 PRL
18 uterus development GO:0060065 9.54 CYP19A1 FOXL2 FSHR
19 chordate embryonic development GO:0043009 9.49 BRCA1 BRCA2
20 oocyte growth GO:0001555 9.46 FOXL2 GDF9
21 gonad development GO:0008406 9.33 AMH CGA FSHR
22 regulation of signaling receptor activity GO:0010469 9.32 AMH BMP15 CGA GDF9 GNRH1 IGF1
23 female gonad development GO:0008585 9.26 BRCA2 CYP19A1 FOXL2 FSHR

Molecular functions related to Ovarian Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 AMH BMP15 GDF9 IGF1
2 protease binding GO:0002020 9.43 BRCA2 INS TNF
3 insulin-like growth factor receptor binding GO:0005159 9.32 IGF1 INS
4 transforming growth factor beta receptor binding GO:0005160 9.13 AMH BMP15 GDF9
5 hormone activity GO:0005179 9.1 AMH CGA GNRH1 IGF1 INS PRL

Sources for Ovarian Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....